

1 **Respiratory cryptosporidiosis in Malawian children with diarrheal disease**

2

3 Pui-Ying Iroh Tam,<sup>1,2,3a</sup> Mphatso Chisala,<sup>1</sup> Wongani Nyangulu,<sup>1b</sup> Herbert Thole,<sup>1</sup> James

4 Nyirenda<sup>1</sup>

5

6 <sup>1</sup> Paediatrics and Child Health Research Group, Malawi-Liverpool Wellcome Trust Clinical

7 Research Programme, Blantyre, Malawi

8 <sup>2</sup> Department of Paediatrics, University of Malawi College of Medicine, Blantyre, Malawi

9 <sup>3</sup> Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United

10 Kingdom

11 <sup>a</sup> Corresponding author: Pui-Ying Iroh Tam, [irohtam@mlw.mw](mailto:irohtam@mlw.mw)

12 <sup>b</sup> Current affiliation: University of Malawi College of Medicine, Blantyre, Malawi

13

14 Running title: Respiratory cryptosporidium in diarrhea

15

16 Keywords: cryptosporidiosis, respiratory tract, gastrointestinal, children, longitudinal

17

18

19

20

21

22

23

24

25

26 **Abstract**

27 Background: Respiratory cryptosporidiosis has been documented in children with diarrhea.

28 We sought to describe the dynamics of respiratory involvement in children hospitalized with

29 gastrointestinal (GI) diarrheal disease.

30

31 Methods: We conducted a prospective, observational longitudinal study of Malawian children

32 2-24 months hospitalized with diarrhea. Nasopharyngeal (NP) swabs, induced sputum and

33 stool specimens were collected. Participants that were positive by cryptosporidium PCR in

34 any of the three compartments were followed up with fortnightly visits up to 8 weeks post-

35 enrollment.

36

37 Results: Of the 162 children recruited, participants had mild-moderate malnutrition, 36 (22%)

38 were PCR-positive for cryptosporidium at enrollment (34 stool, 11 sputum, and 4 NP) and 27

39 completed the majority of follow-up visits (75%). Cryptosporidium was detected in all

40 compartments over the 4 post-enrollment visits, most commonly in stool (94% at enrollment

41 with mean cycle thresholds (Ct) of  $28.8 \pm 4.3$  to 44% at 8 weeks with Ct  $29.9 \pm 4.1$ ), followed

42 by sputum (31% at enrollment with mean Ct  $31.1 \pm 4.4$  to 20% at 8 weeks with Ct  $35.7 \pm 2.6$ ),

43 then NP (11% with mean Ct  $33.5 \pm 1.0$  to 8% with Ct  $36.6 \pm 0.7$ ). Participants with

44 cryptosporidium detection in both the respiratory and GI tract over the study period reported

45 respiratory and GI symptoms in 81% and 62% of study visits, respectively, compared to 68%

46 and 27%, respectively, for those with only GI detection, and had longer GI shedding

47 ( $17.5 \pm 6.6$  v.  $15.9 \pm 2.9$  days).

48

49 Conclusion: Cryptosporidium was detected in both respiratory and GI tracts throughout the 8  
50 weeks post-enrollment. The development of therapeutics for cryptosporidium in children  
51 should target the respiratory as well as GI tract.

52 (255)

53

54

55

### 56 **Author summary**

57 We conducted a prospective, observational longitudinal study of Malawian children 2-24  
58 months hospitalized with diarrhea. Nasopharyngeal (NP) swabs, induced sputum and stool  
59 specimens were collected. Participants that were positive by cryptosporidium PCR in any of  
60 the three compartments were followed up with fortnightly visits up to 8 weeks post-  
61 enrollment. Cryptosporidium was detected by PCR in 21%, 7% and 3% in stool, sputum and  
62 nasopharynx of children hospitalized with diarrhea. Of those positive at enrollment, detection  
63 was noted in 44%, 20%, and 8%, respectively, by 8 weeks post-enrollment.

64 (87)

65

66

67

68

69

70

71

72

73

74 Introduction

75 Cryptosporidiosis is a cause of diarrhea [1-3], excess mortality [4, 5], stunting [1, 6], and is  
76 associated with malnutrition [6, 7]. The Global Enteric Multicenter Study (GEMS) identified  
77 cryptosporidium as second most common cause of diarrhea among infants (0-11 months) in  
78 all four African countries studied (The Gambia, Mali, Mozambique, Kenya) regardless of  
79 HIV prevalence, and among the top five causes for older children (12-23 months) [4].

80 Respiratory cryptosporidiosis has been documented in up to a third of children presenting  
81 with diarrhea [8]; furthermore, respiratory detection without intestinal involvement has been  
82 reported [9, 10], raising the possibility of primary respiratory infection with cryptosporidium,  
83 either by inhalation or by contact with fomites [11].

84

85 Studies have identified cryptosporidium in sputum but have not looked at whether respiratory  
86 involvement is a transient phenomenon or a reservoir for gastrointestinal (GI) disease. This  
87 has implications for therapeutic development. Our primary objective was to evaluate whether  
88 respiratory involvement of cryptosporidium is a transient phenomenon in diarrheal disease,  
89 and to assess for respiratory and GI cryptosporidiosis concurrently and longitudinally in  
90 children hospitalized with diarrheal disease.

91

92 Methods

93 *Study design, setting, and participants.* We conducted a prospective, observational-  
94 longitudinal study of Malawian children hospitalized with diarrhea [12]. Children aged 2-24  
95 months and presenting with primary GI symptoms to Queen Elizabeth Central Hospital in  
96 Blantyre, Malawi, were screened. Eligible patients were those with at least three or more  
97 loose stools within the past 24 hours. Those with dysentery, or visible blood in loose stools,  
98 were excluded.

99

100 *Clinical procedures.* Once written consent was obtained, a detailed history and physical exam  
101 was conducted and all then enrolled subjects had a NP swab, induced sputum, and stool  
102 sample collected. For induced sputum collection, subjects were given a nebulized 3% sodium  
103 chloride mist to inhale for 5-15 minutes. For infants, suctioning of the oropharynx was done  
104 after nebulization to collect the specimen. To ensure safety of the subject, induced sputum  
105 was only collected if there were no contraindications (based on PERCH criteria for induced  
106 sputum collection) [13]: severe hypoxia <92% on supplemental oxygen; inability to protect  
107 airways; severe bronchospasm at admission (defined as continued hypoxia <92% after  
108 appropriate bronchodilator therapy, with other markers of respiratory distress); seizure within  
109 the past 24 hours; or deemed inappropriate by the clinician for another reason (e.g. midface  
110 trauma, inhalational injury, pulmonary effusion, congestive heart failure, congenital heart  
111 disease, etc). If the above symptoms/conditions resolved within 48 hours, induced sputum  
112 collection was reconsidered at that point.

113

114 HIV rapid testing was conducted on infants and, if positive, infants were referred to the  
115 pediatric HIV clinic for further care. Any relevant lab investigations (including full blood  
116 count, urea and electrolytes, liver function tests, malaria parasite screen, blood and/or CSF  
117 culture, TB GeneXpert and AFB testing) performed as part of routine care were recorded.

118

119 All participating children had enrollment NP, sputum and stool specimens evaluated for  
120 cryptosporidium by PCR. Sputum quality was evaluated by microscopy (good quality:  $\leq 10$   
121 squamous epithelial cells/high powered field). Only subjects who were cryptosporidium  
122 PCR-positive on any one of NP/sputum/stool were followed up in the post-enrollment phase

123 up to 8 weeks post-enrollment, with a follow-up visit every two weeks for evaluation of  
124 symptoms, physical assessment, as well as NP/sputum/stool sampling.

125

126 *Laboratory procedures.* DNA was extracted in stool using QIAamp Fast Stool Mini Kit  
127 (Qiagen, Hilden, Germany) and for respiratory tract using the QIAamp DNA mini kit  
128 (Qiagen) for cryptosporidium, and UCP Mini kit (Qiagen) for respiratory co-pathogens.  
129 Cryptosporidium detection of specimens at enrollment were measured using quantitative  
130 polymerase chain reaction (qPCR), with appropriate positive and negative controls and a  
131 positive result being a cycle threshold (Ct) <35. In subsequent follow-up samples in stool,  
132 cryptosporidium was detected using qPCR in a TaqMan Array Card (Thermo Fisher,  
133 Waltham, MA) using a custom design developed at the Houghton Laboratory (Charlottesville,  
134 VA) [14] and tested for 28 enteropathogens. In sputum, for multiplex PCR we used the  
135 respiratory pathogens 33 kit (Fast Track Diagnostics, Luxembourg, Luxembourg).

136

137 *Statistical analysis.* Frequencies and proportions of observed levels were reported for binary  
138 and categorical variables, with exact binomial 95% confidence intervals given where  
139 appropriate. Comparisons were performed using the Fisher's exact test for binary and  
140 categorical variables, t-test (two groups) or ANOVA (three or more groups) for  
141 approximately normally distributed variables and Wilcoxon rank sum (2 groups) or Kruskal-  
142 Wallis (3 or more groups) tests for variables with severely nonparametric distributions.  
143 Statistical analysis was performed using Stata software, version 16, and statistical  
144 significance was set at 0.05.

145

146 *Ethical approval.* The study was approved by the University of Malawi College of Medicine  
147 Research Ethics Committee (P.07/18/2438) and the Liverpool School of Tropical Medicine

148 Research Ethics Committee (18-066). Written consent was obtained from parents or  
149 guardians prior to enrollment.

150

## 151 Results

152 From 1 March 2019 to 3 April 2020, 162 children were recruited into the study. Two children  
153 did not submit specimens. Of the remaining 160 children, 36 (23%) were positive in any one  
154 of the three samples collected (34 stool (21%), 11 sputum (7%), and 4 NP (3%)) and were  
155 entered into follow-up. The study was discontinued early due to COVID-19, by which time  
156 27 children had completed at least three of the four follow-up visits (75%).

157

158 Among the 162 children who were hospitalized with diarrhea, the mean age was  $11.6 \pm 5.0$   
159 months, and 59% were male (Table 1). Mean height-for-age, weight-for-age, and weight-for-  
160 height z scores were  $-1.41 \pm 1.5$ ,  $-1.02 \pm 1.2$ , and  $-0.08 \pm 1.6$ , respectively. Nine percent of  
161 mothers were HIV-infected, and one-third of those children tested positive by HIV rapid test  
162 (3% of total). The participants had a mean of  $4.5 \pm 1.4$  persons in a household, and the  
163 majority of children had access to a pit toilet/latrine (95%), piped drinking water (78%), and  
164 harbored a residential animal in the compound (66%). Among the 36 children who were  
165 cryptosporidium PCR-positive, the mean age was  $12 \pm 5.0$  months, 63% were male and two  
166 (6%) were positive by HIV rapid test. No significant differences in characteristics between  
167 children who were cryptosporidium-positive versus -negative were noted (Supplementary  
168 Table 1).

169

170 **Table 1.** Characteristics of children hospitalized with diarrhea at enrollment

Characteristic	Children with diarrhea (n=162)	Cryptosporidium- positive (n=36)	Cryptosporidium- negative (n=124)	P value
----------------	-----------------------------------	-------------------------------------	--------------------------------------	---------

<b>Demographics</b>				
Age, <sup>a</sup> months, mean (SD)	11.6 (5.0)	12 (5.0)	11.6 (5.1)	0.897
2-11 months	90 (56%)	21 (60%)	65 (53%)	0.565
12-24 months	72 (44%)	14 (40%)	58 (47%)	
Male sex	95 (59%)	22 (63%)	72 (59%)	0.649
Highest level of maternal education				
Did not complete any schooling	62 (38%)	14 (40%)	46 (37%)	0.829
Completed primary school	74 (46%)	15 (43%)	57 (46%)	
Completed secondary school and above	18 (11%)	5 (14%)	13 (11%)	
Mother is employed (%)	72 (44%)	19 (54%)	52 (42%)	0.208
Father is employed (%)	150 (93%)	33 (94%)	114 (92%)	0.742
Number of household members (SD)	4.5 (1.4)	4.1 (1.2)	4.6 (1.4)	0.061
Children <5 years (SD)	1.2 (0.5)	1.2 (0.4)	1.2 (0.6)	0.107
Other household members with respiratory symptoms	46 (28%)	13 (37%)	33 (27%)	0.236
Other household members with GI symptoms	13 (8%)	4 (11%)	9 (7%)	0.487
Residential animals in the compound (%)	107 (66%)	21 (20%)	84 (68%)	0.359
Facility for disposing feces in households (%)				
Pit toilet/latrine	154 (95%)	34 (97%)	116 (94%)	0.686



Pour/flush toilet	8 (5%)	1 (2%)	7 (60%)	
<b>Child health indicators</b>				
<b>Mother HIV status (%)</b>				
Positive	15 (9%)	8 (23%)	17 (14%)	0.391
Unknown	55 (34%)	10 (29%)	44 (36%)	
<b>Child HIV rapid test (%)</b>				
Positive	5 (3%)	2 (6%)	3 (2%)	0.158
Unknown/not done	120 (74%)	22 (63%)	95 (77%)	
<b>Breastfeeding status (%)</b>				
No breastfeeding	22 (14%)	5 (14%)	17 (14%)	1.000
Partial breastfeeding	134 (83%)	29 (82%)	101 (82%)	
Exclusive breastfeeding	6 (4%)	1 (3%)	5 (4%)	
<b>Used antibiotics in 7 days before admission (%)</b>				
Used antibiotics in 7 days before admission (%)	99 (61%)	20 (57%)	75 (61%)	0.699
<b>Given intravenous fluids in 7 days before admission (%)</b>				
Given intravenous fluids in 7 days before admission (%)	63 (61%)	15 (43%)	47 (38%)	0.696
<b>Referred to a health facility for a diarrhea episode in the past 7 days (%)</b>				
Referred to a health facility for a diarrhea episode in the past 7 days (%)	136 (84%)	32 (91%)	101 (82%)	0.292
<b>Z score (SD)</b>				
Height-for-age	-1.45 (1.5)	-1.41 (1.5)	-1.46 (1.5)	0.807
Weight-for-age	-1.0 (1.3)	-1.02 (1.2)	-1.02 (1.3)	0.997
Weight-for-height	-0.08 (1.6)	-0.1 (1.6)	-0.12 (1.6)	0.952
<b>MUAC, cm (SD)</b>				
MUAC, cm (SD)	13.7 (1.4)	13.8 (1.3)	13.7 (1.4)	0.692
<b>Bipedal edema (%)</b>				
Bipedal edema (%)	5 (3%)	1 (3%)	4 (3%)	1.000

<b>Enrollment vitals and symptoms</b>				
Temperature, °C (SD)	36.7 (0.7)	36.7 (0.6)	36.8 (0.7)	0.422
Respiratory rate, breaths/min (SD)	36 (6.1)	36.1 (8.5)	36 (5.4)	0.902
Oxygen saturations, % (SD)	98.6 (1.4)	98.6 (1.4)	98.7 (1.4)	0.719
<b>GI symptoms (%)</b>				
Vomiting	70 (43%)	16 (46%)	52 (42%)	0.847
Abdominal pain/ tenderness	65 (40%)	11 (31%)	51 (42%)	0.330
Poor feeding	66 (40%)	14 (40%)	50 (40%)	0.945
Dehydration	90 (56%)	20 (57%)	68 (55%)	0.845
<b>Respiratory symptoms (%)</b>				
Cough	98 (61%)	24 (69%)	72 (59%)	0.283
Runny nose	58 (36%)	16 (46%)	40 (33%)	0.150
Difficulty in breathing	3 (2%)	1 (3%)	2 (2%)	0.531
Wheezing	14 (9%)	4 (11%)	9 (7%)	0.487
Chest indrawings/retractions	2 (1%)	0	2 (2%)	1.000
Crackles	17 (11%)	6 (17%)	10 (8%)	0.125
<b>Cryptosporidium-PCR positive</b>				
Stool (%)	34 (21%)	34 (94%)	0	<0.001
Induced sputum (%)	11 (7%)	11 (31%)	0	<0.001
NP (%)	4 (2%)	4 (11%)	0	<0.001
<b>Sputum quality (%)</b>				
Good (≤10 sq epis/hpf)	131/160 (82%)	29 (81%)	100 (82%)	0.013
Poor (>10 sq epis/hpf)	15/160 (9%)	1 (3%)	14 (12%)	
Unreadable <sup>c</sup>	14/160 (9%)	6 (17%)	8 (7%)	

---

**Outcomes**

---

Mortality, inpatient (%)	NA	0	NA
Mortality, post-discharge (%)	NA	1 (3%)	NA

---

171 GI, gastrointestinal; HPF, high powered field; MUAC, mid-upper arm circumference; NA,

172 not applicable; SD, standard deviation

173 <sup>a</sup>Values are mean (SD).

174

175

176

177 Induced sputum quality at enrollment was good in 81%, poor in 9% and unreadable in 10%,

178 with similar proportions of good quality sputum among cryptosporidium-positive and -

179 negative participants (81% and 82%, respectively). Over the 8-week period, cryptosporidium

180 was detected in both respiratory and GI tracts (Table 2): most commonly in stool (94% at

181 enrollment to 44% at 8 weeks), followed by sputum (31% at enrollment to 20% at 8 weeks),

182 then NP (11% to 8%). Lowest Ct counts were generally noted in the stool (mean Ct 28.8±4.3

183 at enrollment to 29.9±4.1 at 8 weeks), followed by sputum (mean Ct 31.1± 4.4 at enrollment

184 to 35.7±2.6 at 8 weeks), and NP ((mean Ct 33.5±1.0 to 36.6±0.7); Figure 1). We detected

185 cryptosporidium in respiratory but not GI tract in 7 study visits, including 2 at enrollment

186 (stool Ct were above the 35 cutoff and therefore considered negative). Detection in the

187 respiratory tract did not always correlate with symptoms (Figures 2A-O). For individual

188 participants in whom cryptosporidium was detected at enrollment, detection was noted most

189 consistently in the GI tract throughout the 8 weeks. Respiratory co-pathogens were detected

190 in 87/104 (84%) visits over the follow-up period.

191

192 **Table 2.** Longitudinal detection of cryptosporidium in stool and respiratory tract and  
 193 associated symptoms

Characteristics	Study period				
	Enrollment (n=36)	2 weeks <sup>a</sup> (n=27)	4 weeks <sup>b</sup> (n=24)	6 weeks <sup>c</sup> (n=26)	8 weeks <sup>d</sup> (n=25)
<b>Cryptosporidium detection</b>					
Detection in NP	4 (11%)	5 (19%)	2 (8%)	1 (4%)	2 (8%)
NP Ct values <sup>e</sup> (SD)	33.5 (1.0)	33.7 (2.0)	35.6 (0.6)	35.7	36.6 (0.7)
Detection in sputum	11 (31%)	10 (37%)	10 (42%)	8 (31%)	5 (20%)
Sputum Ct values (SD)	31.1 (4.4)	29.9(3.6)	33.0 (2.6)	34.3 (2.9)	35.7 (2.6)
Detection in GI tract	34 (94%)	22 (81%)	16 (67%)	11 (42%)	11 (44%)
Stool Ct values (SD)	28.8 (4.3)	26.0 (4.5)	30.3 (2.8)	31.3 (3.5)	29.9 (4.1)
Detection in respiratory tract only	2 (6%)	0	1 (4%)	2 (8%)	2 (8%)
Detection in GI tract only	26 (72%)	13 (48%)	6 (25%)	3 (12%)	6 (24%)
Detection in respiratory and GI tract	9 (25%)	9 (33%)	9 (26%)	6 (23%)	3 (12%)
<b>Presentation</b>					
Referral to health facility for an illness in the past 7 days	36 (100%)	10 (37%)	6 (25%)	5 (19%)	7 (28%)
Diarrhea in the past 7 days	36 (100%)	0	2 (8%)	4 (15%)	3 (12%)
Respiratory symptoms in the past 7 days <sup>f</sup>	26 (72%)	9/10 (90%)	4/6 (67%)	2/5(40%)	5/7 (71%)
Cough	24 (69%)	5/10 (50%)	2/6 (33%)	2/5 (40%)	5/7 (71%)

Runny nose	16 (46%)	7/10 (70%)	4/6 (67%)	1/5 (20%)	3/7 (43%)
Difficulty in breathing	1 (3%)	0	0	0	0
Wheezing	4 (11%)	3/10 (30%)	1/6 (17%)	1/5 (20%)	0
Chest indrawings/ retractions	0	0	0	0	0
Crackles	6 (17%)	5/10 (50%)	1/6 (17%)	1/5 (20%)	0/7
Vomiting	16 (46%)	0/10	0/6	1/5 (20%)	0/7
Abdominal pain/ tenderness	11 (31%)	1/10 (10%)	1/6 (17%)	1/5 (20%)	0/7
Poor feeding	14 (40%)	0	0	0	0
Other household members with respiratory symptoms	13 (37%)	1/6 (17%)	3/5 (60%)	0	0
Other household members with GI symptoms	4 (11%)	0	3 (13%)	1 (4%)	2 (8%)
<b>Vital signs</b>					
Respiratory rate, breaths/min (SD)	36 (6.1)	34.7 (3.4)	32.8 (3.2)	34.4 (5.7)	32.3 (3.7)
Oxygen saturations, % (SD)	98.6 (1.4)	99.1 (1.2)	98.5 (1.1)	99.4 (0.8)	98.8 (1.4)
<b>Outcome</b>					
Mortality	1 <sup>g</sup> (3%)	0	0	0	0

194 Ct, cycle threshold; GI, gastrointestinal; NP, nasopharynx; SD, standard deviation

195 <sup>a</sup>One child withdrew after enrollment, five did not enter follow-up due to early stopping of  
196 study, and three were lost to follow-up.

197 <sup>b</sup>Three children missed week 4 visit.

198 <sup>c</sup>One child missed week 6 visit.

199 <sup>d</sup>Two children did not complete week 8 visit due to early stopping of study.

200 <sup>e</sup>Values are mean (SD).

201 <sup>f</sup>In follow-up study visits, symptoms were recorded only if these led to health facility referral.

202 <sup>g</sup>Patient died after discharge before the week 2 visit.

203

204

205 Respiratory symptoms were noted in 72% of cryptosporidium-positive participants at  
206 enrollment, the most common symptom being cough (69%), but also included runny nose  
207 (46%), crackles (17%) and wheeze (11%). For those entered into the 8-week follow-up  
208 period, participants with cryptosporidium positivity in the respiratory tract had respiratory  
209 symptoms in 23/43 (53%) of visits.

210

211 Among participants with cryptosporidium detection in both the respiratory and GI tract at  
212 enrollment (Table 3A) compared to those with cryptosporidium detection in the GI tract only,  
213 a larger proportion reported respiratory symptoms (90% v. 65%), and GI shedding of  
214 cryptosporidium was longer ( $14.3\pm 2.1$  v.  $14.1\pm 0.7$  days), but these were not statistically  
215 significant. Among participants whom cryptosporidium was detected in both the respiratory  
216 and GI tract over the 8-week study period compared to GI tract only (Table 3B), a larger  
217 proportion reported respiratory (81% v. 68%) and GI symptoms (62% v. 27%) per study visit,  
218 and GI shedding of cryptosporidium was longer ( $17.5\pm 6.6$  v.  $15.9\pm 2.9$  days), but again these  
219 were not statistically significant.

220

221 **Table 3.** Characteristics and associated symptoms in participants with cryptosporidium  
 222 detection in GI tract only v. GI and respiratory tract A) at enrollment; B) throughout study  
 223 period

Characteristic	At enrollment			Throughout study period		
	GI detection only (n=26)	GI and respiratory detection (n=10)	P value	GI detection only (n=16)	GI and respiratory detection (n=11)	P value
Age, <sup>a</sup> months (SD)	11.3 (5.3)	13 (4.0)	0.370	12.2 (2.3)	12.0 (6.7)	0.922
Male sex	17 (65%)	6 (60%)	0.7664	9 (56%)	8 (72%)	0.448
Z score (SD)						
Height-for-age	-1.4 (2.4)	-1.3 (1.1)	0.896	-1.6 (2.5)	-1.4 (1.9)	0.837
Weight-for-age	-1.1 (1.4)	-0.6 (1.2)	0.319	-1.1 (1.2)	-0.8 (1.2)	0.474
Weight-for-height	-0.2 (1.6)	0.0 (1.7)	0.708	-0.1 (1.7)	0.0 (1.6)	0.945
Number of household members (SD)	4.2 (1.4)	4.3 (1.5)	0.771	4.4 (1.5)	4.1 (0.9)	0.504
Household children <5 years	1.3 (0.7)	1.1 (0.3)	0.449	1.1 (0.1)	1.2 (0.1)	0.696
Pit latrine	25 (96%)	10 (100%)	0.529	16 (100%)	10 (90%)	0.407
Piped water for drinking	4 (15%)	1 (10%)	0.916	2 (13%)	3 (27%)	0.370
Piped water for utensils	18 (69%)	6 (60%)	0.448	13 (81%)	4 (45%)	0.124

Treated water (%)	13 (50%)	2 (20%)	0.142	6 (37%)	5 (45%)	0.710
Residential animals in the compound	14 (54%)	7 (70%)	0.467	11 (69%)	7 (63%)	1.000
Respiratory symptoms	17 (65%)	9 (90%)	0.223	11 (68%)	9 (81%)	0.385
Enrollment oxygen sats, % (SD)	98.5 (1.4)	98.8 (1.2)	0.561	98.5% (1.1)	98.3% (1.7)	0.653
GI symptoms	23 (89%)	8 (80%)	0.603	3 (27%)	10 (62%)	0.120
Duration of GI shedding, <sup>b</sup> days (SD)	14.1 (0.7)	14.3 (2.1)	0.819	15.9 (2.9)	17.5 (6.6)	0.445

224 GI, gastrointestinal; SD, standard deviation

225 <sup>a</sup>Values are mean (SD).

226 <sup>b</sup>N changes to 27 who followed up through study period.

227

228

## 229 Discussion

230 This is the first longitudinal study to evaluate the respiratory cryptosporidiosis in pediatric  
231 diarrheal disease. In children hospitalized with diarrheal disease, cryptosporidium was  
232 detected most frequently in stool, followed by sputum and NP. The most common respiratory  
233 symptom was cough. Longitudinally, we detected cryptosporidium in both respiratory and GI  
234 tracts through 8 weeks post-enrollment, usually at lowest Ct counts in stool, followed by  
235 sputum and then NP. Longer GI shedding of cryptosporidium was noted among those where  
236 we detected cryptosporidium in both the respiratory and GI tracts, compared to GI detection  
237 only, although findings did not reach statistical significance.



238

239 Our cryptosporidium detection rate is far higher than has been reported in diarrhea studies in  
240 sub-Saharan Africa, with rates of positivity ranging from 9% in Kenya to 14.7% in  
241 Mozambique [4, 8]. Subclinical cryptosporidium infection was noted to be high (6%) in  
242 Tanzania [15]. A previous study done at QECH found cryptosporidium to be the third most  
243 common cause of diarrhea with a prevalence in stool of 28% among cases [16]. In our study,  
244 the positivity rate was 21%, and this would be 12% if we used the GEMS diarrheagenic  
245 cutoffs [17]. This thus supports the high prevalence of cryptosporidium infection among  
246 young children hospitalized with diarrheal illness in sub-Saharan Africa.

247

248 Few studies, however, have evaluated the prevalence of respiratory cryptosporidiosis in  
249 pediatric diarrheal disease. A study in Uganda detected cryptosporidium in 35.4% of induced  
250 sputum samples from children presenting with diarrhea who were cryptosporidium-positive  
251 in the stool [8]. In our study, cough was noted in almost two-thirds of children presenting  
252 with diarrhea, and the frequency of respiratory signs and symptoms tended to be higher, but  
253 were not significantly different between those with cryptosporidium-positive and -negative  
254 stool samples. In addition to sampling the lower respiratory tract with induced sputum, we  
255 also collected NP specimens throughout the follow-up period, and documented detection  
256 throughout the 8-week period, although in fewer numbers, more intermittently, and at higher  
257 Ct counts compared to sputum. Respiratory symptoms were more common among those  
258 cryptosporidium-positive in respiratory and GI tract compared to positive in GI tract alone,  
259 although again these findings were not statistically significant. In contrast to the Mor study,  
260 which only collected sputum samples from children with cough, unexplained tachypnea or  
261 hypoxia, we collected respiratory specimens in all participants at enrollment and noted that  
262 participants with cryptosporidium positivity in the respiratory tract had respiratory symptoms

263 in just over half of visits. These data support that almost half the participants with respiratory  
264 cryptosporidium detection are asymptomatic, and is a lower, rather than upper, respiratory  
265 tract pathogen or colonizer [18-21].

266

267 The continued detection of cryptosporidium in both GI and respiratory tract over 8 weeks  
268 may reflect the young age of this population. A study in Bangladesh noted that children  $\leq 2$   
269 years positive for cryptosporidium shed it for a mean of 4.1 weeks, which was significantly  
270 longer than those  $>2$  years (mean 1.7 weeks) [22]. However, that was a household  
271 transmission study and did not evaluate children hospitalized with diarrhea. For respiratory  
272 pathogens, prolonged detection of respiratory viruses has been noted in a community  
273 surveillance study in Utah, with significantly longer detection noted in children  $<5$  years  
274 (mean 1.9 weeks) compared to other age groups (mean 1.6-1.7 weeks) [23]. To our  
275 knowledge, prolonged detection in the respiratory tract has not before been described for a  
276 protozoan parasite, which was not associated with higher prevalence of respiratory  
277 symptoms.

278

279 Prevalence of cryptosporidiosis is higher in cases of persistent v. acute diarrhea (15% v. 6.1%  
280 in a study in Guinea Bissau [5]). Persistent diarrhea has been described for cryptosporidiosis  
281 with duration of up to 5 months among severely immunocompromised infants [24]. In the  
282 Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the  
283 Consequences for Child Health and Development Program (MAL-ED) study,  
284 cryptosporidiosis was the fifth highest attributable pathogen in all pediatric diarrhea in the  
285 community setting, and had increased frequency among those with prolonged and severe  
286 diarrhea [3]. Among our participants, GI symptoms resolved within 2 weeks of  
287 hospitalization for all participants, but cryptosporidium was detected in stool for eight

288 participants throughout the 8-week period. Shedding duration for cryptosporidiosis among  
289 children hospitalized with diarrhea in sub-Saharan Africa has not been described previously  
290 using molecular techniques, although in Malawian HIV-infected adults we documented  
291 consistent shedding for up to 8 weeks [25]. Nutritional status may also account for the  
292 prolonged detection of up to 8 weeks that we documented in our study population. Even  
293 though the mean weight-for-height z score was within normal, the mean height-for-age and  
294 weight-for-age z scores of recruited participants both met WHO criteria for stunting and  
295 wasting, and 41%, 22%, and 10% had height-for-age, weight-for-age, and weight-for-height z  
296 scores <-2, respectively, indicating mild-moderate malnutrition in this population. Reduced  
297 nutritional status could impact host immunity and predisposition to colonization/infection  
298 [26-28].

299

300 Cryptosporidiosis has been associated with excess mortality in children who had the infection  
301 in infancy, and this excess mortality persists into the second year of life [4, 5]. In our study  
302 we had one death, which occurred in a 7 month-old breastfeeding, HIV unknown male. This  
303 child had anthropometric parameters consistent with severe acute malnutrition (mid-upper  
304 arm circumference 11 cm, height-for-age z score -1.85, weight-for-age z score -3.01, weight-  
305 for-height z score -2.47, no nutritional edema) at time of enrollment, and an enrollment  
306 cryptosporidium Ct of 23 in the stool but negative in sputum and NP. At time of enrollment  
307 he was afebrile with normal vitals and had mild dehydration, diarrhea associated with  
308 abdominal tenderness and vomiting, as well as runny nose, cough and wheeze, but no  
309 shortness of breath. Death occurred two weeks after hospitalization after the child developed  
310 a cough and fever and was treated at an outpatient health facility.

311

312 This study has several limitations. The sample size was small, and the study population was  
313 drawn from a single hospital, and therefore findings may not be generalizable to other  
314 settings. Secondly, we did not evaluate for respiratory co-pathogens in our enrollment  
315 specimens, thereby limiting our ability ascribe symptoms to a single pathogen, although we  
316 did document co-pathogen detection in 84% during the follow-up period. Thirdly, we did not  
317 genotype cryptosporidium to ascertain whether re-infections occurred. However, these  
318 limitations are balanced out by the longitudinal observational design, which allowed us to  
319 document for the first time the dynamics of respiratory cryptosporidium among children  
320 hospitalized with diarrheal disease.

321

## 322 Conclusion

323 In summary, in this study we demonstrated that over 20% of young children hospitalized with  
324 diarrheal disease in our setting are positive for cryptosporidium, and they can shed  
325 cryptosporidium in the stool for up to 2 months. Concurrent respiratory cryptosporidiosis can  
326 be detected in a substantial proportion of young children, and detection continues over a  
327 prolonged period, with detection more prominent in the lower rather than upper respiratory  
328 tract. This has implications for the development of therapeutics for cryptosporidiosis, which  
329 is limited currently to nitazoxanide, and which is poorly efficacious in malnourished children  
330 [29, 30]. Since malnourished children are in greatest need for cryptosporidium therapeutics,  
331 scientists have been actively trying to find new, more effective drugs to treat  
332 cryptosporidiosis in this population. Because safety is of paramount concern in this age  
333 group, those developing drugs have debated whether a drug that only resides in the GI tract  
334 would be adequate for treating cryptosporidiosis in malnourished children, compared to one  
335 with broader systemic distribution [31]. Our findings suggest that the respiratory tract is a  
336 significant reservoir for cryptosporidium infection, and that to cure children, may require a

337 drug that distributes to the lungs as well as the GI tract. Thus, future research on therapeutic  
338 development should focus on drugs that target not only the GI but also the respiratory tract.

339

340

341 (2,628 words)

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361 ≡

362 Acknowledgements

363 We thank the patients and parents for participating in this study; research clinical and  
364 laboratory staff for conducting the study; David Moore and Tanja Adams with training the  
365 CryptoResp clinical and laboratory teams; Eric Houpt and Darwin Operario with providing  
366 TAC cards and technical assistance; Neema Toto for interim study support; Thokozani  
367 Ganiza for assistance with data management; and Wes Van Voorhis for reviewing drafts,  
368 providing feedback, and supporting us throughout the whole project.

369

370 Funding

371 The work was supported by the Bill & Melinda Gates Foundation (OPP1191165).

372

373 Author contributions

374 Conceived and designed the study: PI; Performed the study: MC, WN, HT, JN; Analyzed the  
375 data: MC, JN; Supervised the study and wrote first draft of the manuscript: PI; Reviewed,  
376 provided critical feedback, and approved the final draft: all authors.

377

378 Potential conflicts of interest

379 PI has received grants from BMGF outside of the submitted work. All other authors report no  
380 potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential  
381 Conflicts of Interest.

382

383

384

385

386

387 References

- 388 1. Berkman DS, Lescano AG, Gilman RH, Lopez SL, Black MM. Effects of stunting,  
389 diarrhoeal disease, and parasitic infection during infancy on cognition in late  
390 childhood: a follow-up study. *Lancet* **2002**; 359(9306): 564-71.
- 391 2. Lima AA, Moore SR, Barboza MS, Jr., et al. Persistent diarrhea signals a critical  
392 period of increased diarrhea burdens and nutritional shortfalls: a prospective cohort  
393 study among children in northeastern Brazil. *J Infect Dis* **2000**; 181(5): 1643-51.
- 394 3. Platts-Mills JA, Babji S, Bodhidatta L, et al. Pathogen-specific burdens of community  
395 diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). *Lancet*  
396 *Glob Health* **2015**; 3(9): e564-75.
- 397 4. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal  
398 disease in infants and young children in developing countries (the Global Enteric  
399 Multicenter Study, GEMS): a prospective, case-control study. *Lancet* **2013**;  
400 382(9888): 209-22.
- 401 5. Molbak K, Hojlyng N, Gottschau A, et al. Cryptosporidiosis in infancy and childhood  
402 mortality in Guinea Bissau, west Africa. *BMJ* **1993**; 307(6901): 417-20.
- 403 6. Korpe PS, Haque R, Gilchrist C, et al. Natural History of Cryptosporidiosis in a  
404 Longitudinal Study of Slum-Dwelling Bangladeshi Children: Association with Severe  
405 Malnutrition. *PLoS Negl Trop Dis* **2016**; 10(5): e0004564.
- 406 7. Costa LB, JohnBull EA, Reeves JT, et al. Cryptosporidium-malnutrition interactions:  
407 mucosal disruption, cytokines, and TLR signaling in a weaned murine model. *J*  
408 *Parasitol* **2011**; 97(6): 1113-20.
- 409 8. Mor SM, Tumwine JK, Ndeezi G, et al. Respiratory cryptosporidiosis in HIV-  
410 seronegative children in Uganda: potential for respiratory transmission. *Clin Infect*  
411 *Dis* **2010**; 50(10): 1366-72.

- 412 9. Hojlyng N, Jensen BN. Respiratory cryptosporidiosis in HIV-positive patients. *Lancet*  
413 **1988**; 1(8585): 590-1.
- 414 10. Mercado R, Buck GA, Manque PA, Ozaki LS. *Cryptosporidium hominis* infection of  
415 the human respiratory tract. *Emerg Infect Dis* **2007**; 13(3): 462-4.
- 416 11. Sponseller JK, Griffiths JK, Tzipori S. The evolution of respiratory Cryptosporidiosis:  
417 evidence for transmission by inhalation. *Clin Microbiol Rev* **2014**; 27(3): 575-86.
- 418 12. Nyangulu W, Van Voorhis W, Iroh Tam PY. Evaluating respiratory cryptosporidiosis  
419 in pediatric diarrheal disease: protocol for a prospective, observational study in  
420 Malawi. *BMC Infect Dis* **2019**; 19(1): 728.
- 421 13. Grant LR, Hammitt LL, Murdoch DR, O'Brien KL, Scott JA. Procedures for  
422 collection of induced sputum specimens from children. *Clin Infect Dis* **2012**; 54 Suppl  
423 2: S140-5.
- 424 14. Liu J, Kabir F, Manneh J, et al. Development and assessment of molecular diagnostic  
425 tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study. *Lancet*  
426 *Infect Dis* **2014**; 14(8): 716-24.
- 427 15. Korpe PS, Valencia C, Haque R, et al. Epidemiology and Risk Factors for  
428 Cryptosporidiosis in Children From 8 Low-income Sites: Results From the MAL-ED  
429 Study. *Clin Infect Dis* **2018**; 67(11): 1660-9.
- 430 16. Iturriza-Gomara M, Jere KC, Hungerford D, et al. Etiology of Diarrhea Among  
431 Hospitalized Children in Blantyre, Malawi, Following Rotavirus Vaccine  
432 Introduction: A Case-Control Study. *J Infect Dis* **2019**; 220(2): 213-8.
- 433 17. Liu J, Platts-Mills JA, Juma J, et al. Use of quantitative molecular diagnostic methods  
434 to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control  
435 study. *Lancet* **2016**; 388(10051): 1291-301.



- 436 18. Clavel A, Arnal AC, Sanchez EC, et al. Respiratory cryptosporidiosis: case series and  
437 review of the literature. *Infection* **1996**; 24(5): 341-6.
- 438 19. Dupont C, Bougnoux ME, Turner L, Rouveix E, Dorra M. Microbiological findings  
439 about pulmonary cryptosporidiosis in two AIDS patients. *J Clin Microbiol* **1996**;  
440 34(1): 227-9.
- 441 20. Lopez-Velez R, Tarazona R, Garcia Camacho A, et al. Intestinal and extraintestinal  
442 cryptosporidiosis in AIDS patients. *Eur J Clin Microbiol Infect Dis* **1995**; 14(8): 677-  
443 81.
- 444 21. Poirot JL, Deluol AM, Antoine M, et al. Broncho-pulmonary cryptosporidiosis in four  
445 HIV-infected patients. *J Eukaryot Microbiol* **1996**; 43(5): 78S-9S.
- 446 22. Korpe PS, Gilchrist C, Burkey C, et al. Case-Control Study of *Cryptosporidium*  
447 Transmission in Bangladeshi Households. *Clin Infect Dis* **2019**; 68(7): 1073-9.
- 448 23. Byington CL, Ampofo K, Stockmann C, et al. Community Surveillance of  
449 Respiratory Viruses Among Families in the Utah Better Identification of Germs-  
450 Longitudinal Viral Epidemiology (BIG-LoVE) Study. *Clin Infect Dis* **2015**; 61(8):  
451 1217-24.
- 452 24. Kocoshis SA, Cibull ML, Davis TE, Hinton JT, Seip M, Banwell JG. Intestinal and  
453 pulmonary cryptosporidiosis in an infant with severe combined immune deficiency. *J*  
454 *Pediatr Gastroenterol Nutr* **1984**; 3(1): 149-57.
- 455 25. Iroh Tam PY, Arnold SLM, Barrett LK, et al. Clofazimine for treatment of  
456 cryptosporidiosis in HIV-infected adults (CRYPTOFAZ): an experimental medicine,  
457 randomized, double-blind, placebo-controlled phase 2a trial. *Clin Infect Dis* **2020**.
- 458 26. Bourke CD, Jones KDJ, Prendergast AJ. Current Understanding of Innate Immune  
459 Cell Dysfunction in Childhood Undernutrition. *Front Immunol* **2019**; 10: 1728.

- 460 27. Gwela A, Mupere E, Berkley JA, Lancioni C. Undernutrition, Host Immunity and  
461 Vulnerability to Infection Among Young Children. *Pediatr Infect Dis J* **2019**; 38(8):  
462 e175-e7.
- 463 28. Ibrahim MK, Zambruni M, Melby CL, Melby PC. Impact of Childhood Malnutrition  
464 on Host Defense and Infection. *Clin Microbiol Rev* **2017**; 30(4): 919-71.
- 465 29. Checkley W, White AC, Jr., Jaganath D, et al. A review of the global burden, novel  
466 diagnostics, therapeutics, and vaccine targets for cryptosporidium. *Lancet Infect Dis*  
467 **2015**; 15(1): 85-94.
- 468 30. Striepen B. Parasitic infections: Time to tackle cryptosporidiosis. *Nature* **2013**;  
469 503(7475): 189-91.
- 470 31. Huston CD, Spangenberg T, Burrows J, Willis P, Wells TN, van Voorhis W. A  
471 Proposed Target Product Profile and Developmental Cascade for New  
472 Cryptosporidiosis Treatments. *PLoS Negl Trop Dis* **2015**; 9(10): e0003987.
- 473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484

485 **Table 1.** Characteristics of the study population at enrollment

486 **Table 2.** Longitudinal detection of cryptosporidium in GI and respiratory tract and associated  
487 symptoms

488 **Table 3.** Characteristics and associated symptoms in participants with cryptosporidium  
489 detection in GI tract only v. GI and respiratory tract A) at enrollment; B) throughout study  
490 period

491

492 **Supplementary Table 1.** Full characteristics of study population at enrollment

493

494

495 Figure legend

496 **Figure 1.** Comparison of cryptosporidium detection in GI and respiratory tracts (mean cycle  
497 threshold with 95% confidence intervals) over 8 weeks in children hospitalized with diarrheal  
498 disease

499 **Figure 2.** Patient-level dynamics of cryptosporidium detection in GI and respiratory tracts  
500 over 8 weeks in a: A) 10 month-old; B) 14 month-old; C) 9 month-old; D) 12 month-old; E)  
501 14 month-old; F) 7 month-old; G) 7 month-old; H) 11 month-old; I) 14 month-old; J) 11  
502 month-old; K) 17 month-old; L) 10 month-old; M) 13 month-old; N) 20 month-old; and O)  
503 15 month-old.

504

505

506

507

508

509



